Photograph of the members of the Neighborhood Drug Company at a dinner to support the Opera in 2016.  They are from left to right: Maria Ivarsdottir, Hakon Hakonarson, Marian Moskowitz, Dave Moskowitz, Rita Harper, Phil Harper

The Neighborhood Drug Company

The story behind neuroFIx and the Neighborhood drug company

NeuroFix is the polar opposite of a large pharmaceutical company.  It has never had more than two shareholders, two members of the board of directors and two corporate officers.  It has never had a single employee.  It has never paid a salary.  It not only never owned a building, but it never even had an office (it did have a registered office because all corporations have to have a registered office but this was just a mail drop).  It never had its own web page or telephone number.  It never even had a single piece of stationery.  

But neuroFix did have behind it a support group.  It had what came to be called the Neighborhood Drug Company.  The Neighborhood Drug Company is an unincorporated social club, cheering section and advisory panel.  It has six members.  It holds no formal meetings, has no minutes taken, no officers, and it is as informal as a neighborhood barbecue (of which it had many).  Here are the six members. 

Maria Ivarsdottir (Hakon’s wife; in Iceland, wives do not take their husband’s last name but retain their maiden name) and Hakon Hakonarson, Rita and Phil Harper and Marian and David Moskowitz became the Neighborhood Drug Company in 2013.

From the inception of neuroFix to its dissolution, David Moskowitz has been one of the two directors. Phil became the other director in 2013, when he also became the president, CEO and chairman of the board. Hakon has always been the guiding force, the chief scientific advisor, and he was the sole shareholder until Phil became the second shareholder.

During the clinical trial starting in January 2015 and continuing until May 2015, the three couples that are the members of the Neighborhood Drug Company met often for dinner on the weekend (usually Sunday night) at either the Moskowitz house or the Hakonarson house to hear from Hakon how the clinical trial was proceeding. Each of the six participants was excited about the prospect that the drug being tested, NFC-1, was achieving, on a weekly basis, astonishing results in improving the lives of the patients taking the drug.